These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 17718660)

  • 1. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
    Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY
    Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.
    LeLorier J; Duh MS; Paradis PE; Latrémouille-Viau D; Lefebvre P; Manjunath R; Sheehy O
    Curr Med Res Opin; 2008 Apr; 24(4):1069-81. PubMed ID: 18315941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
    LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
    Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
    Andermann F; Duh MS; Gosselin A; Paradis PE
    Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.
    Paradis PE; Latrémouille-Viau D; Moore Y; Mishagina N; Lafeuille MH; Lefebvre P; Gaudig M; Duh MS
    Curr Med Res Opin; 2009 Jul; 25(7):1793-805. PubMed ID: 19505202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risks and costs of multiple-generic substitution of topiramate.
    Duh MS; Paradis PE; Latrémouille-Viau D; Greenberg PE; Lee SP; Durkin MB; Wan GJ; Rupnow MF; LeLorier J
    Neurology; 2009 Jun; 72(24):2122-9. PubMed ID: 19528520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
    Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
    Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
    Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD
    JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden associated with the use of generic antiepileptic drugs in the United States.
    Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM
    Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.
    Hartung DM; Middleton L; Svoboda L; McGregor JC
    CNS Drugs; 2012 Aug; 26(8):707-16. PubMed ID: 22731934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical and economic impact of generic drugs in the treatment of epilepsy].
    Argumosa A; Herranz JL
    Rev Neurol; 2005 Jul 1-15; 41(1):45-9. PubMed ID: 15999330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
    Duh MS; Cahill KE; Paradis PE; Cremieux PY; Greenberg PE
    Expert Opin Pharmacother; 2009 Oct; 10(14):2317-28. PubMed ID: 19663636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Low prescription rates of generic lamotrigine and gabapentine].
    Mattsson P; Lindqvist T
    Lakartidningen; 2008 Feb 6-12; 105(6):385. PubMed ID: 18380362
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
    Makus KG; McCormick J
    Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
    Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
    Davis KL; Candrilli SD; Edin HM
    Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
    Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
    Contin M; Alberghini L; Candela C; Benini G; Riva R
    Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic substitution in the treatment of epilepsy: patient and physician perceptions.
    Berg MJ; Gross RA; Haskins LS; Zingaro WM; Tomaszewski KJ
    Epilepsy Behav; 2008 Nov; 13(4):693-9. PubMed ID: 18589000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.